CSPC Innovation subsidiary gets clinical trial approval for SYS6040
CSPC Innovation Pharmaceutical (SZSE:300765) announced that its holding subsidiary, CSPC OBI Pharmaceutical, received a "Drug Clinical Trial Approval Notice" from the National Medical Products Administration for its SYS6040 antibody-drug conjugate. SYS6040, classified as a Class 1 therapeutic biological product, is indicated for advanced solid tumors and will proceed to clinical trials. Preclinical studies suggest SYS6040 has shown good anti-tumor activity in various cancers. CSPC Innovation Pharmaceutical acknowledges the risks inherent in drug development, including potential trial failures and regulatory hurdles, and advises investors to exercise caution.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when CSPC Innovation Pharmaceutical publishes news
Free account required • Unsubscribe anytime